Skip to main content
Equibles
ANIK logo

ANIK · Anika Therapeutics, Inc.

Track ANIK — free

Use ANIK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$20.81 -0.19 (-0.90%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 53% of revenue

One customer — 53% of revenue (the three-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the three-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
View the 10-Q filed Jul 29, 2026
Market Cap
$278.50M
Shares
13.38M

ANIK metrics

73 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$20.81
Market cap
$278.50M

Price action

19 metrics
Price change (1W)
-1.4%
Price change (30D)
-2.8%
Price change (3M)
+43.7%
Price change (6M)
+47.4%
Price change (YTD)
+116.5%
Price change (1Y)
+128.9%
Trailing year
Price change (5Y)
-48.7%
52-week high
$22.03
52-week low
$8.40
Change from 52-week high
-5.5%
Change from 52-week low
+147.7%
Annualized volatility
49.9%
Beta
0.7
RSI (14D)
54.6
Price vs SMA 50
+13.2%
Price vs SMA 200
+49.2%
Avg volume (3M)
96,009
Relative volume
1.0
Average dollar volume
$1.77M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
13.38M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.3×
reciprocal yield 43.0%
P / book
2.0
reciprocal yield 48.9%
FCF yield
0.2%
TTM · current market cap
Buyback yield
5.4%
P / FCF
499.4
reciprocal yield 0.2%
P / operating cash flow
47.0
reciprocal yield 2.1%
Earnings yield
-1.3%

Historical valuation

8 metrics
P / E historical average (3Y)
43.2×
reciprocal yield 2.3%
P / E historical average (5Y)
43.2×
reciprocal yield 2.3%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
5.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
62.2%
Operating margin
-4.2%
Trailing 12 months
Net margin
-3.1%
Gross profit (TTM)
$75.00M
Operating profit (TTM)
−$5.12M
Net income (TTM)
−$3.78M
Trailing 12 months
Diluted EPS (TTM)
$-0.27
FCF margin
0.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$6.32

Growth

11 metrics
Revenue growth YoY
+15.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$120.65M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-5.5%
Year over year · fewer shares
Revenue CAGR (3Y)
-0.3%
Revenue CAGR (5Y)
-2.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-17.5%

Quality

14 metrics
Return on equity
-2.8%
Return on assets
-2.1%
Debt / equity
—
Current ratio
4.5
EBITDA (TTM)
$500,000
Free cash flow (TTM)
$562,000
Quick ratio
3.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$38.41M
Total assets
$183.47M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$5.98M
Capital expenditures (TTM)
$5.42M
R&D (TTM)
$27.45M
SG&A (TTM)
$52.67M
Stock compensation (TTM)
$13.15M
R&D / revenue
22.8%
Stock compensation / revenue
10.9%

Ownership (13F)

3 metrics
13F filers
134
13F filer change QoQ
+4
Institutional ownership
91.4%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 2.3 days to cover
Days to cover
2.3d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
$41,060
Insider-sentiment score
78 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 898437 CUSIP 035255108 13F (30d) 99 filings 99 filers Visit website Investor relations